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Abstract
Dual-energy X-ray absorptiometry (DXA) was the first imaging tool widely utilized by clinicians to assess fracture risk,
especially in postmenopausal women. The development of DXA nearly coincided with the availability of effective
osteoporosis medications. Although osteoporosis in adults is diagnosed based on a T-score equal to or below − 2.5 SD,
most individuals who sustain fragility fractures are above this arbitrary cutoff. This incongruity poses a challenge to
clinicians to identify patients who may benefit from osteoporosis treatments. DXA scanners generate 2 dimensional
images of complex 3 dimensional structures, and report bone density as the quotient of the bone mineral content
divided by the bone area. An obvious pitfall of this method is that a larger bone will convey superior strength, but
may in fact have the same bone density as a smaller bone. Other imaging modalities are available such as peripheral
quantitative CT, but are largely research tools. Current osteoporosis medications increase bone density and reduce
fracture risk but the mechanisms of these actions vary. Anti-resorptive medications (bisphosphonates and denosumab)
primarily increase endocortical bone by bolstering mineralization of endosteal resorption pits and thereby increase
cortical thickness and reduce cortical porosity. Anabolic medications (teriparatide and abaloparatide) increase the
periosteal and endosteal perimeters without large changes in cortical thickness resulting in a larger more structurally
sound bone. Because of the differences in the mechanisms of the various drugs, there are likely benefits of selecting a
treatment based on a patient’s unique bone structure and pattern of bone loss. This review retreats to basic principles
in order to advance clinical management of fragility fractures by examining how skeletal biomechanics, size, shape,
and ultra-structural properties are the ultimate predictors of bone strength. Accurate measurement of these skeletal
parameters through the development of better imaging scanners is critical to advancing fracture risk assessment and
informing clinicians on the best treatment strategy. With this information, a “treat to target” approach could be
employed to tailor current and future therapies to each patient’s unique skeletal characteristics.
Keywords: Osteoporosis, Dual X-ray absorptiometry, Peripheral quantitative computed tomography, Skeletal fracture,
Skeletal biomechanics, Bisphosphonates, Denosumab, Teriparatide, Romosozumab
Background
Two million osteoporosis fractures occur in the U.S.
each year costing approximately $19 billion [1]. Despite
the medical and economic costs of fragility fractures,
osteoporosis screening is often overlooked and viewed as
a low priority. Dual-energy X-ray absorptiometry (DXA)
was introduced in the mid-1980s as a rapid and safe im-
aging modality to estimate bone mineral density (BMD)
and predict skeletal fracture risk [2]. Up until the wide-
spread use of DXA, patients at high fracture risk were
not easily identified and effective osteoporosis medica-
tions were limited. Today, not only are DXA scanners
utilized in hospital radiology departments but they are
also found at many physician group outpatient clinical
practices.
The World Health Organization (WHO) defines
osteoporosis as a BMD T-score of − 2.5 or lower at any
one location or having a previous fragility fracture. The
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rationale for choosing this T-score was that the propor-
tion of postmenopausal women with a T-score less than
− 2.5 is equal to the fragility fracture lifetime risk of 30%
[3]. It was expected that individuals who were below this
T-score would have a greater fracture risk. Further, this
cutoff value of − 2.5 was expected to change over time
as the accumulation of experience and data would pro-
vide insight into a more appropriate cutoff value. How-
ever, this cutoff value has not changed in over 25 years
despite data indicating that the T-score of − 2.5 captures
only approximately 50% of women with fragility frac-
tures [4]. There is less consensus of the definition of
osteoporosis in men. The WHO, however, recommends
similar T-score thresholds in men who are greater or
equal to 50 years of age [5]. Because of a larger skeletal
structure, fracture risk for men is less than in women for
any similar T-score; and the fracture risk in men is less
than half of women starting at age 55 [6]. Even though
fracture rates are less than in men, the mortality associ-
ated with fractures is significantly higher [7, 8].
Thus, individuals with a T-score below the − 2.5 cutoff
may be at higher risk of fracturing but they do not ac-
count for the majority of fracture cases in either women
or men [9, 10]. While one of the challenges in manage-
ment is to avoid over-treatment, individuals with T-
scores above − 2.5 with other risks for fracture deserve
attention, and should qualify for appropriate treatment
as well.
Other commonly used methods to predict fracture
risk such as the FRAX scoring system, trabecular
bone score and bone turnover markers may provide
an incremental improvement in risk assessment when
combined with DXA. Ultimately, skeletal biomechan-
ics that include size, shape and bone molecular
structure are the predictors of bone strength. Under-
standing how each of these variables affects the skel-
eton is critical in the development of better fracture
prediction tools to accurately identify those at a high
risk for fractures.
Bone biomechanics
The adult skeleton is composed of 206 uniquely shaped
structures, each of which coordinately adapts its morph-
ology and tissue-level material properties to support the
physiological loads encountered during daily activities.
Cortical bone is the dense outer shell that is divided into
three surfaces: the periosteum, intracortical pores, and
endosteum (Fig. 1). Trabecular bone is surrounded by
cortical bone and is comprised of a spongy network of
connected plates and rods. To remain strong but light,
the system uses cortical bone in the diaphyses and tra-
becular bone surrounded by a relatively thin cortical
shell in the metaphyseal regions. The proportion of
cortical and trabecular bone varies depending on the lo-
cation. For example, the ultradistal radius is approxi-
mately 25% cortical and 75% trabecular bone. The 1/3
proximal radius is primarily all cortical bone.
The determinants of bone strength are complex but
can be divided into four basic components: size, shape,
architecture and composition (Fig. 2). Bone has a unique
ability to coordinately adjust these traits. This results in
a structure that is sufficiently stiff to resist habitual loads
but minimizes mass, keeping the overall energy of move-
ment to a minimum. The overall strength of a bone de-
pends on the proportion of cortical and trabecular
tissues, their morphologies and their material properties,
and the interactions among these traits. An individual’s
unique genetic program also contributes to bone
Fig. 1 Structural characteristics of bone. Bone is comprised of a dense cortical shell that surrounds a spongy trabecular bone network. The
periosteal diameter combined with the endosteal diameter determines cortical thickness. The size of bone along with cortical thickness and
porosity significantly contribute to bone strength. The inner trabecular compartment contains a network of plates and rods that also contribute
to bone strength
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strength; it is estimated that up to 70% of ultimate bone
strength and structure is genetically determined [11].
Bone size
The pubertal transition is the critical period in which
bone size is ultimately determined. Under the influence
of androgens, the periosteum undergoes expansion
resulting in a greater bone cross-sectional area [12].
Endosteal resorption occurs simultaneously but not at
the rate of periosteal apposition. The end result is a lar-
ger bone and thicker cortex. Estrogens also direct an in-
crease in periosteal expansion but not to the degree of
androgens. Women generally also have less endosteal
bone resorption ultimately leading to a larger bone, al-
though smaller than in men, but the strength is main-
tained and compensated by a relatively thicker cortex
compared to men. Overall, the relatively smaller bone
size in women translates to an increased risk for
fracture.
Bone shape
Each of the 206 bones is generally well adapted to resist
their habitual loads. This process, called functional adap-
tation, occurs primarily during growth and results in a
biological system that is robust to the relatively narrow
range of daily loads. Habitual loading is an important
contributor to bone modeling and remodeling, and ul-
timately bone shape. Bone surfaces that experience the
greatest compressive or tensile loads respond with in-
creased bone mass. Conversely, skeletal unloading leads
to increased bone resorption and bone loss. Daily activ-
ities result in a load (force) being applied to the bones of
the skeleton, whether weight bearing or non-weight
bearing. These loads cause the bone to deform with the
amount of deformation being dependent on the applied
load and the stiffness of the structure. A stiff structure
will deform less than a compliant structure under the
same load. These loads are generally small enough that
the system returns to its original state when the load is
removed.
Because bone is well adapted to these habitual loads,
this process may leave the bone vulnerable or weak to
loads applied in a different direction, such as during a
fall. For example, the proximal femur is extremely strong
when loaded in a direction consistent with habitual
forces. A healthy femur can withstand nearly 8 kN
(~ 1800 pounds) before breaking, and so theoretically
two femurs should be able to support the weight of an
average car. However, the strength of the proximal femur
declines by more than 50% when loaded in a direction
consistent with that seen during a fall to the side [13]. The
mass and material properties are the same regardless of
the loading direction, but the orientation of these traits
relative to the two loading directions differs greatly. Under
a fall-to-the-side loading direction, it is the amount of
bone mass remaining within the femur that represents the
resistance to fracturing.
Bone architecture
Bone architecture, the trabecular arrangement combined
with cortical bone thickness and porosity, provides a
scaffold that is significantly stronger than an equal mass
of solid bone. The trabecular bone scaffold within the
marrow space is composed of plates and rods (Fig. 1)
Fig. 2 Determinants of bone strength. Bone strength is a composite summation of numerous skeletal characteristics. The size of bone increases
with age and with puberty. Ultimate bone size also has a large genetic contribution. Genetics and habitual loading determine bone shape. The
architecture of bone is a complex interplay among many structural components. Cortical diameter, thickness and porosity contribute to cortical
strength. The number, thickness, and the connectivity of plates and rods determine trabecular bone strength. Bone composition is difficult to
measure non-invasively. The degree of collagen crosslinking and the density of collagen contribute to bone matrix strength. Newly formed
protein matrix subsequently becomes mineralized and how the hydroxyapatite crystals are arranged within the matrix and the degree of
mineralization contribute to bone hardness and strength
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with a higher plate:rod ratio conferring strength. With
aging, plates become more rod-like and plate connectiv-
ity with the rods declines, all of which contributes to
lower bone strength and stiffness.
The arrangement of trabecular bone is strategic to
provide maximal strength. This is especially evident in
the femoral neck [14, 15]. The ability of the inferior cor-
tex and compressive arcade to resist compressive loads,
combined with the superior cortex and tensile arcade to
resist tensile loads provides maximal strength and flexi-
bility (Fig. 3). Failure of this cooperative network is the
reason for femoral neck fractures. Thus, efforts to maintain
strength by applying more or greater loads to stimulate
bone formation may make the bone stronger for daily
loads. Unfortunately, upon losing appreciable bone mass in
the femur (e.g., tensile arcade), it remains unclear whether
an exercise program will be able to restore lost tissue.
Cortical porosity is another layer that defines cortical
strength independent of cortical size. Heightened osteo-
clast resorption expand existing Haversian canals, creat-
ing large macro-pores and leading to the progressive
thinning of the cortical tissue that is capable of bearing
load. With age, pore volume increases but pore number
remains relatively constant [16]. It is mechanically for-
tuitous that the resorptive process begins near the endo-
cortical surface. The proximate location of these
macropores minimizes the impact on bone strength
compared to pores created closer to the periosteal surface
[17–19]. Despite this biomechanically favorable location
of bone loss, cortical porosity is a strong predictor of frac-
ture especially in the cortical rich area of the forearm [20].
Osteoclast resorption and resultant porosity of the tra-
becular bone surface also contributes to bone fragility.
Bone composition
Bone quality was originally defined as the factors
contributing to strength that are not explained by BMD.
From a clinical perspective, this definition provides a
name to unexplained factors. From an engineering
perspective, this definition makes little sense as it does
not provide a definable biomechanical pathway linking
strength to physical bone traits and ultimately to the
underlying biology [21]. The composition of bone that
contributes to bone quality—the regular arrangement of
collagen, the degree of crosslinking of adjacent collagen
fibrils and mineral to protein matrix ratio—all contribute
to bone quality. Diseases such as Paget’s disease, diabetes
mellitus, and osteogenesis imperfecta and long-term use
of glucocorticoids contribute to poor bone quality.
Another example of decreased bone quality are stress
fractures that occur due to repetitive damage. High bone
turnover is also another component that leads to poor
bone quality. Bone turnover markers have been reported
to be predictive of fracture risk that is independent of
BMD [22–24]. Clinical tests to assess bone quality are
currently being developed but are not available for rou-
tine clinical use.
Skeletal biomechanical changes with puberty and aging
Net bone loss or formation is dependent on the balance
between bone resorption and bone formation. The net
bone formation of skeletal “modeling” of childhood
Fig. 3 Strategic arrangement of cortical and trabecular bone. The proximal femur experiences forces in different directions. a The critical aspects
of femoral neck strength superimposed onto a hip DXA scan image. b With standing, the femoral neck experiences compress forces on the
inferior surface and tensile forces on the superior surface. Compressive loads are reinforced with a compressive arcade composed of a thickened
inferior cortex and an additional trabecular network. The tensile arcade is reinforced with a network of trabecular bone. These reinforcements are
combined with lateral and medial cortices that provide additional reinforcements against side-to-side forces. NanoCT images were taken at
27 μm resolution using a phoenix nanotom-s (GE Sensing and Inspection Technologies, GmbH, Wunstorf, Germany)
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ensures structural support during the critical growth
period. Before puberty, skeletal development is nearly
identical in boys and girls. New bone formation on the
periosteum exceeds endosteal bone breakdown resulting
in skeletal expansion. Trabecular bone continues to de-
velop in this period. Until the period of peak bone mass
at 30-40 years of age in men and women, total skeletal
bone formation is greater than resorption. With aging,
and especially at menopause, this balance tips toward re-
sorption and bone loss. After the period of peak bone
mass, men and women lose similar amounts of cortical
bone by endosteal resorption, but men have greater peri-
osteal apposition than women, so that in men, net bone
loss is less. Both sexes experience trabecular bone loss
with aging, but this effect is more pronounced in women
than in men. The decline in estrogen at menopause pro-
motes loss of trabecular connectivity and exerts a pro-
found impact on bone strength [25].
Tools currently available to assess fracture risk
DXA
Despite its underappreciated limitations, DXA is often
considered to be the gold standard imaging test for diag-
nosing osteoporosis. Unlike older DXA machines that
employed higher radiation, today’s scanners emit signifi-
cantly less radiation per scan—as little as 1-10 microsie-
verts (μSv) with about 7 μSv being the average ionizing
radiation dose received from natural background radi-
ation [26]. DXA is widely available in hospital and out-
patient practices. By utilizing two different energies this
technology is able to differentiate the mineralized bone,
composed of hydroxyapatite, from soft tissues such as
skin, fat and muscle. The two X-ray energies differ in
their attenuation profiles after passing through bone and
soft tissues. Older DXA units employed a pencil beam
that had a limited scan area resulting in longer scan
times. Modern DXA units use a fan-shaped beam that
translates to scan times of 10-30 s. Standard DXA scans
report bone density in grams/cm2 and is derived from
dividing the bone mineral content (BMC) in grams by
the region of interest (ROI) scanned in cm2.
The standard locations for DXA measurement are the
L1-L4 lumbar spine, hip, and forearm. These reference
locations were originally selected because morbidity
from fractures at these locations is high, especially at the
spine and hip. DXA results are reported as the standard
deviation (SD) from a population mean, comparing the
subject to a population at peak bone mass (T-score) and
to an age-matched population (Z-score). One and two
SDs from the mean encompass 68 and 95% of a popula-
tion, respectively. Since peak bone mass occurs at be-
tween 30 and 40 years of age, it is appropriate to use Z-
scores in children and young adults who have yet to
achieve peak bone mass.
The distribution of bone density across a population is
dependent on race, age and gender. For example,
African-Americans have lower rates of fracture com-
pared to US Caucasians and Asians and this parallels the
population distribution differences among races [27]. In
one study, the age-adjusted mean for femoral neck BMD
was 0.686 g/cm2 in US Caucasians and 0.841 g/cm2 in
African Americans [28]. Because of such racial and eth-
nic differences, the significance of T-scores must be con-
sidered based on the fracture risk of ethnic and racially
matched persons. A similar rationale can be applied to
men who have larger skeletal structures compared to
women. To control for racial differences, DXA calculates
T-scores using normative databases based on NHANES
III data that include non-Hispanic White, Black, His-
panic and Asian individuals [29]. A pediatric normative
base is also available.
As stated before, bone size is directly related to
strength. DXA does not account for bone size in asses-
sing fracture risk. Attempts to correct bone size for
height and weight have been reported [30]. Some DXA
manufacturers allow for weight correction in the calcula-
tion of Z-scores to adjust for an expected decrease in
fracture risk as weight increases. Height correction is
especially important in assessing fracture risk in children
affected by short stature or growth delay [31].
DXA images are a 2-dimensional (vertical and hori-
zontal) condensation of a 3-dimensional structure. As
such, bone thickness is not measured in this scan. The
BMC measured reflects the amount of cortical and
trabecular tissue present within a structure that acts to
attenuate the X-ray signal; bones with more tissue
attenuate the signal to a greater degree resulting in a
higher gray value and BMC measure. Bone area is a
measure of the size of the ROI. For the hip, the ROI
width is fixed and thus variation in bone area reflects
differences in external bone size. The ratio of these two
variables provides a measure of the mass density but not
a measure of morphology or material properties. Further,
BMD does not differentiate whether the variation in
BMD arises from differences in cortical mass, trabecular
mass, or external bone size.
Conventional wisdom is that women uniformly lose
endosteal and trabecular bone in a similar pattern. Re-
cent data however suggest that the pattern of bone loss
with aging in women is not uniform [32]. Bone shape
and size at the menopause transition may in fact have a
critical role in determining long-term bone loss with
aging. Women with narrower femoral necks experienced
modest decreases in BMC compared to those with wider
femoral necks (Fig. 4). But, women with narrow femoral
necks also had larger increases in femoral neck area
compared to women with wider femoral necks. BMD is
the quotient of the BMC divided by the area. Because
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the larger increase in the denominator (area) in women
with narrow femoral necks is similarly matched by the lar-
ger decrease in the numerator (BMC) in women with wide
femoral necks, the result is that both groups have similar
losses in BMD over time but for very different reasons.
The impact of these structural and mass changes on
strength is currently under investigation. In addition to
the previous discussion regarding how most fragility frac-
tures occur in persons with T-scores > − 2.5, this example
illustrates another limitation of DXA scanning to accur-
ately predict bone strength and fracture risk.
Trabecular bone score (TBS)
Other than BMD, fracture risk is dependent on bone
geometry, microarchitecture, microdamage, rate of bone
turnover, and mineralization—all of which contribute to
bone strength. TBS indirectly assesses skeletal texture
using DXA images and can be used to predict the risk of
spine and hip fractures in women and men above the
age of 40. It has been validated in multiple cohorts with
large numbers of subjects and shown to improve frac-
ture risk prediction beyond that obtained by DXA. TBS
is available for clinical use in the United States [33].
The TBS is a textural index based on evaluating the
pixel gray-level variations in the lumbar DXA image
[34]. Well-structured bone produces 2-D DXA images
that are homogenous with small gray-value amplitude
variations. On the other hand, bone that is of poor qual-
ity produces higher gray-value amplitudes. TBS is a unit-
less calculation of the sum of the squared gray-level
differences between pixels at a specific distance. The
steeper slope represents well-structured bone while the
lower slope is suggestive of poorer architecture. Based
on values provided by the manufacturer, TBS > 1.350 is
normal, 1.200-1.350 is consistent with partially degraded
bone and < 1.200 indicates degraded bone.
TBS is typically measured at the L1-L4 lumbar spine
(LS), the same sites used for DXA. The results are pro-
vided for each vertebral body as well as the composite
for L1-L4. Unlike DXA, osteoarthritic changes have little
impact on data generated by TBS.
Several studies have shown that TBS predicts clinical,
hip and vertebral fractures in postmenopausal women
[35, 36]. Some longitudinal studies have reported that
TBS predicts fracture risk in men over the age of 40 but
data on premenopausal women are lacking [37, 38]. In
addition, a meta-analysis of 14 prospective population-
based cohorts reported that TBS provided additional
information on the 10-year fracture probability as esti-
mated by the standard FRAX tool [39].
A new feature is available on the online FRAX risk
assessment tool with an option to “adjust with TBS”. A
Fig. 4 Areal BMD as determined by DXA declines with aging for different reasons. With aging, women with smaller femoral necks tend to
increase bone area through an increase in cortical thickness by an increase in periosteal and endosteal bone formation. Since BMD may only
decrease slightly but bone area increases more, the result is lower areal BMD as measured by DXA despite likely having little change in bone
strength. In the case of women with larger femoral necks, the endosteal cortex undergoes excessive resorption without periosteal expansion
resulting in a thinner cortex. The result is a lower BMC without significant change in bone area. The DXA areal BMD decreases and may result in
a bone with less strength. Adapted from Jepsen, et al. JBMR 2017 [32]
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low TBS would increase the FRAX risk of major osteo-
porotic fracture by 1.5-1.6 fold [40]. Changes in TBS are
much smaller than LS BMD with osteoporosis treatment
and therefore the role of using TBS to monitor patients
on therapy is uncertain. There is no data on the impact
of a change in TBS on fracture risk.
Quantitative US (QUS)
QUS can provide information on bone structure and fra-
gility. Due to its use of low-frequency ultrasound it is
safe and a relatively inexpensive method to assess for
osteoporosis. The two main parameters measured are
the velocity of sound (VOS) and broadband US attenu-
ation (BUA). Data provided by QUS of the heel have
been shown to correlate with the risk of fracture [41]
but it is not used routinely for diagnosis of osteoporosis.
Quantitative CT (QCT)
QCT provides volumetric 3D measurements by utilizing
a low dose scan protocol and offers adequate details of
the cortical and trabecular bone to generate reasonable
estimates of strength through engineering-based analyses
such as finite element analysis (FEA) and probabilistic
modeling. QCT is most commonly studied at the lumbar
spine and hip. A variation of QCT, high-resolution per-
ipheral quantitative computed tomography (HR-pQCT),
is mostly used to assess tibia and radius bone architec-
ture and density. The associations between HR-pQCT-
based vertebral bone measurements and prevalent verte-
bral fractures depend on the spinal locations of both
bone measurement and fracture [42, 43]. An unclear
correlation between QCT and other non-vertebral osteo-
porotic fractures along with higher exposure to ionizing
radiation and cost have resulted in an infrequent use of
these scans. In addition, large precision errors with re-
peat measurements and unclear methods to adjust for
variation in marrow fat and soft tissue density remain
challenges for wider clinical use of QCT.
Fracture risk assessment calculators
Until recently, treatment decisions were made primarily
using T-scores but the over-reliance on this score has re-
sulted in over-treatment, especially in younger patients
who may in fact have a lower fracture risk. Clinical risk
factors, such as age, previous fragility fracture, parental
history of hip fracture at age < 80, smoking, excessive al-
cohol intake, and prolonged glucocorticoid use, all have
been shown to confer risk independent of BMD meas-
urement. Using these risk factors and BMD data, frac-
ture prediction algorithms have been developed.
The FRAX scoring system (https://www.sheffield.ac.
uk/FRAX/) is one such fracture prediction algorithm
[44]. It is the most widely used fracture prediction algo-
rithm. The score provides a 10-year probability of having
a hip or major osteoporotic fracture with or without data
on femoral neck BMD. The algorithm has been well vali-
dated in independent cohorts [45]. The Garvan calculator
is another tool used to predict fracture risk (https://www.
garvan.org.au/promotions/bone-fracture-risk/calculator/).
The calculator was developed using data obtained from
the Dubbo Osteoporosis Epidemiology Study at Sydney’s
Garvan Institute. In addition to demographic variables
and BMD or T-scores, the Garvan calculator takes into ac-
count the number of falls. The tool has been validated and
is found to be clinically useful in predicting fractures in
those at high risk [46]. Other calculators such as Osteo-
porosis Canada and FORE FRC v 2.0 predict the 10-year
fracture risk but are not commonly used. The Male Osteo-
porosis Risk Estimation Score (MORES) was reported to
be a better tool to predict hip osteoporosis in men
compared to FRAX [47]. While acknowledging that these
calculators do not include all risk factors and can underesti-
mate the fracture risk, they serve as a valuable tool to assist
physicians in assessing risk with one long-term goal of
avoidance of treatment in patients at low fracture risk [48].
Bone turnover markers (BTMs)
BTMs are released during bone remodeling and can be
measured in blood or urine. BTMs provide an assess-
ment of bone remodeling rate and are surrogate end-
points for fracture, bone quality and effectiveness of the
therapy. They are grouped into two broad categories:
bone resorption and bone formation markers. Collagen
degradation products, namely C-terminal cross-linked
telopeptide of type 1 collagen (βCTX), are released
during bone resorption and reflect osteoclast activity.
Bone formation markers such as procollagen type I N-
terminal propeptide (PINP) and procollagen type I C-
terminal propeptide (PICP) are peptides derived from
posttranslational cleavage of type I procollagen mole-
cules by proteases at the N- and C-terminus, respect-
ively. These markers reflect osteoblast function and
activity.
Commercially available βCTX assays have been devel-
oped with low method-specific difference and inter-
assay variability. βCTX itself demonstrates significant
variation due to circadian rhythm and food intake. It is
best measured in the fasted state and in the morning.
The International Osteoporosis Foundation recommends
using PINP and βCTX to assess bone formation and
bone resorption, respectively [24].
The utility of bone turnover markers in assessing the
risk of fracture has been studied in postmenopausal
women. In the OFLEY cohort, healthy postmenopausal
women who had BTMs in the highest quartile were
noted to have a two-fold increase in the risk of fractures
with a RR of 1.8% [49]. In another cohort of older post-
menopausal women, high levels of osteocalcin (bone
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formation marker) were associated with a higher risk of
fractures [50]. BTMs can also be used for monitoring
osteoporosis treatment. In the IMPACT study, greater
than 30% decline in the level of urine NTX was associ-
ated with a 50% reduction in non-vertebral fractures
[51]. In postmenopausal women treated with teripara-
tide, an increase in P1NP at three months correlated
with an increase in LS BMD at 18 months [52].
While there has been widespread use of these
markers for monitoring therapy in osteoporosis, treat-
ment goals based on fracture reduction have not been
defined. In addition, there is insufficient data on the
use of bone turnover markers for diagnosis of osteo-
porosis, identifying candidates for treatment, and de-
termination of the length of bisphosphonate “drug
holidays”.
Treatment-related changes in bone density and
architecture
Antiresorptive and anabolic therapies increase spine and
hip BMD, with the highest increases in the spine
(Table 1). As newer agents are studied, a trend in more
efficacious BMD improvement with each new agent is
apparent. Although many osteoporosis treatments have
not been directly compared in head-to-head trials, the
mechanisms of actions of these newer treatments often
predict a superior efficacy in increasing BMD.
All approved osteoporosis medications produce sig-
nificant increases in spine and hip BMD as measured
by DXA. The degree of BMD increase in the spine is
likely a consequence of the greater surface area of
trabecular-rich vertebral bodies on which the agents
act. Twelve months of treatment with bisphospho-
nates increased BMD by approximately 4% in the
spine and 2% in the hip as reported in the landmark
FIT, VERT, BONE, and Horizon trials [53–56]. The
efficacy of daily, weekly and monthly oral and yearly
IV bisphosphonate medications are similar [57–61].
Compliance with oral bisphosphonates is a common
factor in those patients who fail to respond to treat-
ment [62–64]. Denosumab has even greater effects
likely owing to its enhanced ability to suppress bone
resorption [65]. Teriparatide, an anabolic agent, in-
creases spine and hip BMD [66]. Abaloparatide, an-
other recently available anabolic agent, also markedly
increases spine and hip BMD [67].
Romosozumab, not yet approved for treatment, is a
humanized monoclonal antibody that targets sclerostin,
and has been reported to increase spine BMD approxi-
mately 13.5% and hip BMD approximately 6.5% after
12 months of treatment [68, 69].
Table 1 Summary of treatment-related changes in human skeletal architecture. Only published studies that reported defined skeletal
architectural indices were included in the Table
Areal BMD HR-pQCT, QCT QCT Bone biopsy/QCT
Location Spine Hip Radius/Tibia Spine Hip
Measure BMD
(Approx. % increase)
Per.Diam CoPo CtTh Tb CoPo CtTh BV/TV CoPo CtTh BV/TV
Bisphosphonates 4(a) 2-2.5(a) ↓,NS(g) ↑ (g) ↑,NS(g) ↓(m) NS(m)
Denosumab 5.5(b) 3(b) ↓,NS(h) ↑(h) ↑(h) ↓(n)
Teriparatide 9(c) 3(c) ↑(f) ↑,NS(i) ↑,NS (i) ↑,↓(i) NS(j) ↑(k) ↑(0) ↑(p) ↑(p)
Abaloparatide 11(d) 4(d)
Romosozumab 13.5(e) 6.5(e) ↑(l) ↑(l) ↑ (l)
BMD bone mineral density, Per.Diam periosteal diameter, CoPo cortical porosity, CtTh cortical thickness; Tb trabecular indices; BV/TV bone volume/tissue volume,
NS not significant, HR-pQCT high-resolution peripheral quantitative computed tomography, QCT quantitative computed tomography
Notes:
a. 12 months of treatment [53, 54, 56, 81, 82]
b. 12 months of treatment [65]
c. 18 months of treatment [66]
d. 18 months of treatment [67]
e. 12 months of treatment [68, 69]
f. [71]
g. Cortical volumetric BMD (Ct vBMD) as a surrogate for CtPo, Tb = Tb vBMD [83]; CtTh significant only for tibia, Tb vBMD increased at tibia [84]; Ct vBMD as a
surrogate for CtPo with difference only in tibia [85, 86]
h. CoPo as a surrogate for Ct vBMD, Tb as a marker of trabecular volumetric BMD (Tb vBMD) [83]; [70, 87]
i. 24 months of treatment [70]; 18 months of treatment, increase in plate Tb number and thickness [88]; 18 months of treatment, increase in trabecular number
[89]; 18 months of treatment, increase in CtTh in tibia only, reduction in trabecular thickness [90]
j. [91]
k. [92]
l. [91, 93]
m. [94]
n. [95]
o. [96]
p. [97]
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Numerous published studies have reported the archi-
tectural changes in the skeleton with such agents using a
variety of techniques that include HR-pQCT and QCT
of in situ hip and spine as well as similar techniques of
iliac crest bone biopsy samples. What has become clear
is that they do not uniformly produce similar results
(Table 1, Fig. 5). Bisphosphonates increase cortical thick-
ness primarily by decreasing the endosteal perimeter,
partially through the filling in of previously excavated re-
sorption pits at the endosteal surfaces. In addition,
bisphosphonates also reduce cortical porosity and in-
crease the amount of trabecular bone. Denosumab has
similar effects and presumably to a higher degree owing
to its improved fracture reduction compared to
bisphosphonates.
Teriparatide has unusual effects on cortical bone.
While spine and hip BMD increased with this agent,
forearm BMD declined prompting a closer inspection of
architectural changes in cortical-rich areas [66]. Teri-
paratide increases cortical porosity through two not mu-
tually exclusive mechanisms: 1) increased osteocyte-
directed bone resorption and 2) enhanced cortical
periosteal bone expansion that leaves a larger proportion
of under-mineralized bone [70–72]. Furthermore, since
the denominator in the BMD calculation is bone area
and teriparatide certainly causes an increase in periosteal
diameter compared to BMC, BMD expectedly decreases.
Presumably abaloparatide has similar effects but such
detailed human architectural analyses have not been
published. Romosozumab is reported to increase cortical
thickness and trabecular bone volume, but how this
agent affects cortical porosity and bone size has not been
published.
The future of goal-directed therapy
Goal-directed treatment for osteoporosis has been advo-
cated as a superior strategy rather than treatment deci-
sions made solely on DXA T-scores [73]. Rather than
arbitrary recommendations to treat osteoporosis for 5 or
10 years with oral bisphosphonates or 3 to 6 years with
IV bisphosphonates, depending on T-scores or whether
a patient is deemed either low or high risk for fracture,
treatment length should ideally be based on achieving a
particular fracture risk threshold [74]. The FRAX risk
Fig. 5 Structural changes in bone with osteoporosis medications. The anti-resorptive medications (bisphosphonates and denosumab) and ana-
bolic medications (teriparatide and likely abaloparatide) produce very different structural changes in bone. Although both classes increase tra-
becular bone, their effects on cortical bone are different. Bisphosphonates and denosumab do not expand periosteal bone but do decrease the
endosteal diameter by an increase in endosteal bone volume. Anti-resorptives also reduce cortical porosity. Anabolic agents lead to an increase
in periosteal bone with a simultaneous increase in endosteal bone resorption resulting in a bone without a large change in cortical thickness. At
the same time, anabolic agents increase cortical porosity. Despite the increase in cortical porosity, the larger bone has increased strength.
NC = no change
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stratification system has raised awareness among clini-
cians that other strong risk factors for fracture exist
other than DXA T-scores—age, previous fragility frac-
ture, high fall risk, long-term glucocorticoid use and
other diseases associated with high fracture risk that in-
clude diabetes mellitus. However, neither bone size nor
architectural makeup is routinely measured but clearly
have large impacts on bone strength. For example, the
femoral neck of two individuals could have the same
BMD but the structure of these could be vastly different
owing to the differences in size with a smaller femoral
neck possessing lower strength. The bone area is already
routinely reported in DXA scans but is not routinely uti-
lized to assess risk. However, recent data support that
bone size is dynamic and that postmenopausal women
with smaller femoral neck size may in fact be at lower
risk for fracture as they age compared to women with
larger femoral neck size due to adapted changes with
aging [32]. How these inter-individual differences in the
age-changes of structure and mass affect bone strength
and fracture has yet to be fully determined.
New imaging techniques that not only measure BMD
but also measure critical indices directly related to frac-
ture risk such as bone size, porosity, cortical thickness,
trabecular volume and the mineral to matrix ratio are
needed. Even better, having such a device that is afford-
able and appropriately sized allowing clinicians to assess
fracture risk in the clinic is the future of osteoporosis
care. Until the radiation dose of QCT is lower, such im-
aging modalities are not practical for routine screening
and treatment monitoring. Methods to directly measure
bone quality such as reference point indentation are in-
vestigative. This method is limited by pain, differing out-
come measures amongst cohorts [75–77] and are
inconsistently related to traditional tissue-level mechan-
ical properties [78, 79]. Compact ultrasound imaging de-
vices that measure forearm cortical bone size and
trabecular bone density is an exciting new area [80].
With advancing imaging methods, we can envision a
treatment strategy whereby osteoporosis medications are
selected based on individual skeletal characteristics. For
example, patients with larger bones, and thinner and
porous cortices may benefit from bisphosphonates and
denosumab, to reduce endocortical resorption that
would ultimately increase cortical thickness. Conversely
in patients with smaller bones whose cortex is not espe-
cially porous, teriparatide or abaloparatide may provide
maximal bone strength. Clearly, this is an area of further
research.
Conclusions
The challenges to wider clinical utilization of biomech-
anical traits in treatment decisions involve 1) better un-
derstanding of biomechanical principles, 2) developing
an appreciation of how bone strength depends on mul-
tiple traits, 3) incorporating the concept that people
fracture for different biomechanical reasons, and 4) co-
alescing this information into a digestible outcome par-
ameter that can be used clinically are areas where more
work is needed. Using these sophisticated technologies,
clinicians will be able to select therapy that targets skel-
etal characteristics. While much work remains in re-
defining and identifying individuals at risk of fractures,
updating the current system of diagnosis and generating
new technologies, we inch closer to the future of osteo-
porosis care and personalized medicine.
Abbreviations
BMC: Bone mineral content; BMD: Bone mineral density; BTM: Bone turnover
marker; DXA: Dual-energy X-ray absorptiometry; HR-pQCT: High-resolution
peripheral quantitative computed tomography; LS: Lumbar spine; P1CP: Procollagen
type I C-terminal propeptide; P1NP: Procollagen type I N-terminal propeptide;
QCT: Quantitative computed tomography; QUS: Quantitative ultrasound; ROI: Region
of interest; SD: Standard deviation; TBS: Trabecular bone score; WHO: World Health
Organization; βCTX: C-terminal cross-linked telopeptide of type 1 collagen;
μSv: Microsieverts
Funding
This work was supported in part by grants from the NIH (AR065424,
AR069620 to KJJ).
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or
analyzed during the current study.
Authors’ contributions
PC, KJJ, and GAC were involved in the drafting, revising and final approval of
the manuscript.
Ethics approval and consent to participate
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Metabolism, Endocrinology & Diabetes, Department of Internal
Medicine, University of Michigan, Ann Arbor, MI, USA. 2Departments of
Orthopaedic Surgery and Biomedical Engineering, University of Michigan,
Ann Arbor, MI, USA. 3Endocrinology Section, Ann Arbor VA Medical Center,
2215 Fuller Road, Research 151, Ann Arbor, MI 48105-2399, USA.
Received: 21 November 2017 Accepted: 27 April 2018
References
1. What is Osteoporosis and What Causes It? Arlington: National Osteoporosis
Foundation. https://www.nof.org/patients/what-is-osteoporosis/.
2. Wahner HW, Dunn WL, Brown ML, Morin RL, Riggs BL. Comparison of dual-
energy x-ray absorptiometry and dual photon absorptiometry for bone
mineral measurements of the lumbar spine. Mayo Clin Proc. 1988;63:1075–84.
3. Kanis JA. Assessment of fracture risk and its application to screening for
postmenopausal osteoporosis: synopsis of a WHO report. WHO study group.
Osteoporos Int. 1994;4:368–81.
4. Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA,
Seeman E. Half the burden of fragility fractures in the community occur in
Choksi et al. Clinical Diabetes and Endocrinology  (2018) 4:12 Page 10 of 13
women without osteoporosis. When is fracture prevention cost-effective?
Bone. 2006;38:694–700.
5. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A
reference standard for the description of osteoporosis. Bone. 2008;42:467–75.
6. Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically
defined population. J Epidemiol Community Health. 1990;44:241–5.
7. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after
all major types of osteoporotic fracture in men and women: an
observational study. Lancet. 1999;353:878–82.
8. Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R.
Survival and potential years of life lost after hip fracture in men and age-
matched women. Osteoporos Int. 2002;13:731–7.
9. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification
of osteopenic women at high risk of fracture: the OFELY study. J Bone
Miner Res. 2005;20:1813–9.
10. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E,
Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA. Fracture incidence
and association with bone mineral density in elderly men and women: the
Rotterdam study. Bone. 2004;34:195–202.
11. Ralston SH, Uitterlinden AG. Genetics of osteoporosis. Endocr Rev. 2010;31:
629–62.
12. Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R,
Vanderschueren D, Manolagas SC. Estrogens and androgens in skeletal
physiology and pathophysiology. Physiol Rev. 2017;97:135–87.
13. Keyak JH, Skinner HB, Fleming JA. Effect of force direction on femoral fracture
load for two types of loading conditions. J Orthop Res. 2001;19:539–44.
14. Singh M, Nagrath AR, Maini PS. Changes in trabecular pattern of the upper
end of the femur as an index of osteoporosis. J Bone Joint Surg Am. 1970;
52:457–67.
15. Zebaze RM, Jones A, Knackstedt M, Maalouf G, Seeman E. Construction of
the femoral neck during growth determines its strength in old age. J Bone
Miner Res. 2007;22:1055–61.
16. Chen H, Zhou X, Shoumura S, Emura S, Bunai Y. Age- and gender-
dependent changes in three-dimensional microstructure of cortical and
trabecular bone at the human femoral neck. Osteoporos Int. 2010;21:627–36.
17. Bjornerem A, Bui QM, Ghasem-Zadeh A, Hopper JL, Zebaze R, Seeman E.
Fracture risk and height: an association partly accounted for by cortical
porosity of relatively thinner cortices. J Bone Miner Res. 2013;28:2017–26.
18. Shigdel R, Osima M, Ahmed LA, Joakimsen RM, Eriksen EF, Zebaze R,
Bjornerem A. Bone turnover markers are associated with higher cortical
porosity, thinner cortices, and larger size of the proximal femur and non-
vertebral fractures. Bone. 2015;81:1–6.
19. Bjornerem A. The clinical contribution of cortical porosity to fragility
fractures. Bonekey Rep. 2016;5:846.
20. Bala Y, Zebaze R, Ghasem-Zadeh A, Atkinson EJ, Iuliano S, Peterson JM,
Amin S, Bjornerem A, Melton LJ 3rd, Johansson H, et al. Cortical porosity
identifies women with osteopenia at increased risk for forearm fractures. J
Bone Miner Res. 2014;29:1356–62.
21. Jepsen KJ, Silva MJ, Vashishth D, Guo XE, van der Meulen MC. Establishing
biomechanical mechanisms in mouse models: practical guidelines for
systematically evaluating phenotypic changes in the diaphyses of long
bones. J Bone Miner Res. 2015;30:951–66.
22. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone
turnover predict postmenopausal forearm bone loss over 4 years: the
OFELY study. J Bone Miner Res. 1999;14:1614–21.
23. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical
indices of bone turnover and the assessment of fracture probability.
Osteoporos Int. 2002;13:523–6.
24. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A,
McClung M, Morris HA, Silverman S, Trenti T, et al. Markers of bone turnover for
the prediction of fracture risk and monitoring of osteoporosis treatment: a
need for international reference standards. Osteoporos Int. 2011;22:391–420.
25. Seeman E. Age- and menopause-related bone loss compromise cortical and
trabecular microstructure. J Gerontol A Biol Sci Med Sci. 2013;68:1218–25.
26. Fogelman I, Blake GM. Different approaches to bone densitometry. J Nucl
Med. 2000;41:2015–25.
27. Cauley JA. Defining ethnic and racial differences in osteoporosis and
fragility fractures. Clin Orthop Relat Res. 2011;469:1891–9.
28. Nam HS, Kweon SS, Choi JS, Zmuda JM, Leung PC, Lui LY, Hill DD, Patrick
AL, Cauley JA. Racial/ethnic differences in bone mineral density among
older women. J Bone Miner Metab. 2013;31:190–8.
29. Third National Health and Nutrition Examination Survery (NHANES III), Bone
Densitometry Manual. Arlington: National Osteoporosis Foundation. https://
wwwn.cdc.gov/nchs/data/nhanes3/manuals/bone.pdf.
30. Carey JJ, Delaney MF. T-scores and Z-scores. Clinical Review of Bone and
Mineral Metabolism. 2010;8:113–21.
31. Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, Mahboubi
S, Shepherd JA, Hangartner TN, Frederick MM, et al. Height adjustment in
assessing dual energy x-ray absorptiometry measurements of bone mass
and density in children. J Clin Endocrinol Metab. 2010;95:1265–73.
32. Jepsen KJ, Kozminski A, Bigelow EM, Schlecht SH, Goulet RW, Harlow SD,
Cauley JA, Karvonen-Gutierrez C. Femoral neck external size but not aBMD
predicts structural and mass changes for women transitioning through
menopause. J Bone Miner Res. 2017;32:1218–28.
33. Martineau P, Silva BC, Leslie WD. Utility of trabecular bone score in the evaluation
of osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2017;24:402–10.
34. Pothuaud L, Carceller P, Hans D. Correlations between grey-level variations
in 2D projection images (TBS) and 3D microarchitecture: applications in the
study of human trabecular bone microarchitecture. Bone. 2008;42:775–87.
35. Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed
by TBS predicts osteoporotic fractures independent of bone density: the
Manitoba study. J Bone Miner Res. 2011;26:2762–9.
36. Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV, Hans D.
Lumbar spine texture enhances 10-year fracture probability assessment.
Osteoporos Int. 2014;25:2271–7.
37. Leslie WD, Aubry-Rozier B, Lix LM, Morin SN, Majumdar SR, Hans D. Spine
bone texture assessed by trabecular bone score (TBS) predicts osteoporotic
fractures in men: the Manitoba bone density program. Bone. 2014;67:10–4.
38. Schousboe JT, Vo T, Taylor BC, Cawthon PM, Schwartz AV, Bauer DC, Orwoll
ES, Lane NE, Barrett-Connor E, Ensrud KE. Osteoporotic fractures in men Mr
OSSRG: prediction of incident major osteoporotic and hip fractures by
trabecular bone score (TBS) and prevalent radiographic vertebral fracture in
older men. J Bone Miner Res. 2016;31:690–7.
39. McCloskey EV, Oden A, Harvey NC, Leslie WD, Hans D, Johansson H,
Barkmann R, Boutroy S, Brown J, Chapurlat R, et al. A meta-analysis of
trabecular bone score in fracture risk prediction and its relationship to FRAX.
J Bone Miner Res. 2016;31:940–8.
40. McCloskey EV, Oden A, Harvey NC, Leslie WD, Hans D, Johansson H, Kanis
JA. Adjusting fracture probability by trabecular bone score. Calcif Tissue Int.
2015;96:500–9.
41. Moayyeri A, Adams JE, Adler RA, Krieg MA, Hans D, Compston J, Lewiecki
EM. Quantitative ultrasound of the heel and fracture risk assessment: an
updated meta-analysis. Osteoporos Int. 2012;23:143–53.
42. Anderson DE, Demissie S, Allaire BT, Bruno AG, Kopperdahl DL, Keaveny TM,
Kiel DP, Bouxsein ML. The associations between QCT-based vertebral bone
measurements and prevalent vertebral fractures depend on the spinal
locations of both bone measurement and fracture. Osteoporos Int. 2014;25:
559–66.
43. Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud
KE, Cummings SR, Orwoll E, Black DM, et al. Prediction of new clinical
vertebral fractures in elderly men using finite element analysis of CT scans. J
Bone Miner Res. 2012;27:808–16.
44. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the
assessment of fracture probability in men and women from the UK.
Osteoporos Int. 2008;19:385–97.
45. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P,
Cooper C, Christiansen C, Cummings S, et al. The use of clinical risk factors
enhances the performance of BMD in the prediction of hip and osteoporotic
fractures in men and women. Osteoporos Int. 2007;18:1033–46.
46. Bolland MJ, Siu AT, Mason BH, Horne AM, Ames RW, Grey AB, Gamble GD,
Reid IR. Evaluation of the FRAX and Garvan fracture risk calculators in older
women. J Bone Miner Res. 2011;26:420–7.
47. Cass AR, Shepherd AJ, Asirot R, Mahajan M, Nizami M. Comparison of the
male osteoporosis risk estimation score (MORES) with FRAX in identifying
men at risk for osteoporosis. Ann Fam Med. 2016;14:365–9.
48. van Geel TA, Eisman JA, Geusens PP, van den Bergh JP, Center JR, Dinant
GJ. The utility of absolute risk prediction using FRAX(R) and Garvan fracture
risk calculator in daily practice. Maturitas. 2014;77:174–9.
49. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of
bone turnover, endogenous hormones and the risk of fractures in
postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:
1526–36.
Choksi et al. Clinical Diabetes and Endocrinology  (2018) 4:12 Page 11 of 13
50. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD.
Undercarboxylated osteocalcin measured with a specific immunoassay
predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol
Metab. 1997;82:719–24.
51. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB. Bone turnover
markers and bone mineral density response with risedronate therapy:
relationship with fracture risk and patient adherence. J Bone Miner Res.
2011;26:1662–9.
52. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM,
Wagman RB. Early changes in biochemical markers of bone formation
predict BMD response to teriparatide in postmenopausal women with
osteoporosis. J Bone Miner Res. 2005;20:962–70.
53. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC,
Bauer DC, Genant HK, Haskell WL, Marcus R, et al. Randomised trial of effect of
alendronate on risk of fracture in women with existing vertebral fractures.
Fracture intervention trial research group. Lancet. 1996;348:1535–41.
54. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M,
Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, et al. Effects of risedronate
treatment on vertebral and nonvertebral fractures in women with
postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy
with Risedronate therapy (VERT) study group. JAMA. 1999;282:1344–52.
55. Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A,
Felsenberg D, Huss H, Gilbride J, Schimmer RC, et al. Effects of oral
ibandronate administered daily or intermittently on fracture risk in
postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.
56. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F,
Lakatos P, Leung PC, Man Z, et al. Once-yearly zoledronic acid for treatment
of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.
57. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes
AJ, Roux C, Levine MA, Uebelhart B, et al. Two-year results of once-weekly
administration of alendronate 70 mg for the treatment of postmenopausal
osteoporosis. J Bone Miner Res. 2002;17:1988–96.
58. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li
Z, Balske A, Lindsay R. The efficacy and tolerability of risedronate once a
week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int.
2002;71:103–11.
59. Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL,
Man Z, Eusebio RA, Beary JF, Burgio DE, et al. Efficacy and safety of
risedronate 150 mg once a month in the treatment of postmenopausal
osteoporosis. Bone. 2008;42:36–42.
60. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL,
Christiansen C, Rowell L, Mairon N, Bonvoisin B, et al. Efficacy and
tolerability of once-monthly oral ibandronate in postmenopausal
osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;
65:654–61.
61. Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF. Intravenous zoledronic
acid and oral alendronate in patients with a low trauma fracture: experience
from an osteoporosis clinic. Intern Med J. 2011;41:186–90.
62. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S.
Adherence to bisphosphonate therapy and fracture rates in osteoporotic
women: relationship to vertebral and nonvertebral fractures from 2 US
claims databases. Mayo Clin Proc. 2006;81:1013–22.
63. Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick
AR, Mogun H, Solmon DH. Gaps in treatment among users of osteoporosis
medications: the dynamics of noncompliance. Am J Med. 2007;120:251–6.
64. Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H,
Solomon DH. The complex relation between bisphosphonate adherence
and fracture reduction. J Clin Endocrinol Metab. 2010;95:3251–9.
65. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas
P, Zoog HB, Austin M, Wang A, et al. Denosumab for prevention of fractures in
postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.
66. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY,
Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, et al. Effect of
parathyroid hormone (1-34) on fractures and bone mineral density in
postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.
67. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P,
Zerbini CA, Hu MY, Harris AG, et al. Effect of Abaloparatide vs placebo on
new vertebral fractures in postmenopausal women with osteoporosis: a
randomized clinical trial. JAMA. 2016;316:722–33.
68. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S,
Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, et al. Romosozumab
treatment in postmenopausal women with osteoporosis. N Engl J Med.
2016;375:1532–43.
69. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T,
Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for
fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:
1417–27.
70. Tsai JN, Nishiyama KK, Lin D, Yuan A, Lee H, Bouxsein ML, Leder BZ. Effects
of Denosumab and Teriparatide transitions on bone microarchitecture and
estimated strength: the DATA-switch HR-pQCT study. J Bone Miner Res.
2017;32:2001–9.
71. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA,
Dalsky GP, Myers SL. Effects of teriparatide [recombinant human parathyroid
hormone (1-34)] on cortical bone in postmenopausal women with
osteoporosis. J Bone Miner Res. 2003;18:539–43.
72. Zebaze R, Seeman E. Cortical bone: a challenging geography. J Bone Miner
Res. 2015;30:24–9.
73. Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM,
Brown TD, Cheung AM, Cody K, Cooper C, et al. Goal-directed treatment for
osteoporosis: a progress report from the ASBMR-NOF working group on
goal-directed treatment for osteoporosis. J Bone Miner Res. 2017;32:3–10.
74. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA,
Compston JE, Drake MT, Edwards BJ, Favus MJ, et al. Managing osteoporosis
in patients on long-term bisphosphonate treatment: report of a task force
of the American Society for Bone and Mineral Research. J Bone Miner Res.
2016;31:16–35.
75. Zysset PK, Guo XE, Hoffler CE, Moore KE, Goldstein SA. Mechanical
properties of human trabecular bone lamellae quantified by
nanoindentation. Technol Health Care. 1998;6:429–32.
76. Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S. In vivo
assessment of bone quality in postmenopausal women with type 2
diabetes. J Bone Miner Res. 2014;29:787–95.
77. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM. Bone material
strength index as measured by impact microindentation is low in patients
with fractures irrespective of fracture site. Osteoporos Int. 2017;28:2433–7.
78. Allen MR, McNerny EM, Organ JM, Wallace JM. True gold or pyrite: a review
of reference point indentation for assessing bone mechanical properties in
vivo. J Bone Miner Res. 2015;30:1539–50.
79. Krege JB, Aref MW, McNerny E, Wallace JM, Organ JM, Allen MR. Reference
point indentation is insufficient for detecting alterations in traditional
mechanical properties of bone under common experimental conditions.
Bone. 2016;87:97–101.
80. Stein EM, Rosete F, Young P, Kamanda-Kosseh M, McMahon DJ, Luo G,
Kaufman JJ, Shane E, Siffert RS. Clinical assessment of the 1/3 radius using a
new desktop ultrasonic bone densitometer. Ultrasound Med Biol. 2013;39:
388–95.
81. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E,
Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, et al. Effect of
alendronate on risk of fracture in women with low bone density but
without vertebral fractures: results from the fracture intervention trial. JAMA.
1998;280:2077–82.
82. Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich
RD, Watts NB, Schimmer RC, Recker RR. Ibandronate produces significant,
similar antifracture efficacy in north American and European women: new
clinical findings from BONE. Curr Med Res Opin. 2005;21:391–401.
83. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E,
Kearns A, Thomas T, Boyd SK, Boutroy S, et al. Microarchitectural
deterioration of cortical and trabecular bone: differing effects of denosumab
and alendronate. J Bone Miner Res. 2010;25:1886–94.
84. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A
longitudinal HR-pQCT study of alendronate treatment in postmenopausal
women with low bone density: relations among density, cortical and
trabecular microarchitecture, biomechanics, and bone turnover. J Bone
Miner Res. 2010;25:2558–71.
85. Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, de Vernejoul
MC. Effect of oral monthly ibandronate on bone microarchitecture in
women with osteopenia-a randomized placebo-controlled trial. Osteoporos
Int. 2013;24:311–20.
86. Bala Y, Chapurlat R, Cheung AM, Felsenberg D, LaRoche M, Morris E, Reeve
J, Thomas T, Zanchetta J, Bock O, et al. Risedronate slows or partly reverses
cortical and trabecular microarchitectural deterioration in postmenopausal
women. J Bone Miner Res. 2014;29:380–8.
Choksi et al. Clinical Diabetes and Endocrinology  (2018) 4:12 Page 12 of 13
87. Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ,
Fuerst T, Wang H, Austin M, Libanati C. Denosumab improves density and
strength parameters as measured by QCT of the radius in postmenopausal
women with low bone mineral density. Bone. 2010;47:131–9.
88. Nishiyama KK, Cohen A, Young P, Wang J, Lappe JM, Guo XE, Dempster
DW, Recker RR, Shane E. Teriparatide increases strength of the peripheral
skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-
pQCT study. J Clin Endocrinol Metab. 2014;99:2418–25.
89. Hansen S, Hauge EM, Beck Jensen JE, Brixen K. Differing effects of PTH 1-34,
PTH 1-84, and zoledronic acid on bone microarchitecture and estimated
strength in postmenopausal women with osteoporosis: an 18-month open-
labeled observational study using HR-pQCT. J Bone Miner Res. 2013;28:736–45.
90. Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK. Changes in trabecular
and cortical bone microarchitecture at peripheral sites associated with 18
months of teriparatide therapy in postmenopausal women with
osteoporosis. Osteoporos Int. 2011;22:357–62.
91. Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C,
Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C. Effects of
Romosozumab compared with Teriparatide on bone density and mass at
the spine and hip in postmenopausal women with low bone mass. J Bone
Miner Res. 2017;32:181–7.
92. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock
MM, Gluer CC, Zysset PK. Improvements in vertebral body strength under
teriparatide treatment assessed in vivo by finite element analysis: results
from the EUROFORS study. J Bone Miner Res. 2009;24:1672–80.
93. Graeff C, Campbell GM, Pena J, Borggrefe J, Padhi D, Kaufman A, Chang S,
Libanati C, Gluer CC. Administration of romosozumab improves vertebral
trabecular and cortical bone as assessed with quantitative computed
tomography and finite element analysis. Bone. 2015;81:364–9.
94. Chavassieux P, Meunier PJ, Roux JP, Portero-Muzy N, Pierre M, Chapurlat R.
Bone histomorphometry of transiliac paired bone biopsies after 6 or 12
months of treatment with oral strontium ranelate in 387 osteoporotic
women: randomized comparison to alendronate. J Bone Miner Res. 2014;29:
618–28.
95. Zebaze R, Libanati C, McClung MR, Zanchetta JR, Kendler DL, Hoiseth A,
Wang A, Ghasem-Zadeh A, Seeman E. Denosumab reduces cortical porosity
of the proximal femoral shaft in postmenopausal women with osteoporosis.
J Bone Miner Res. 2016;31:1827–34.
96. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL,
Black DM. Femoral bone strength and its relation to cortical and trabecular
changes after treatment with PTH, alendronate, and their combination as
assessed by finite element analysis of quantitative CT scans. J Bone Miner
Res. 2008;23:1974–82.
97. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant
human parathyroid hormone (1-34) [teriparatide] improves both cortical
and cancellous bone structure. J Bone Miner Res. 2003;18:1932–41.
Choksi et al. Clinical Diabetes and Endocrinology  (2018) 4:12 Page 13 of 13
